References
- K.W. Tsang, P.L. Ho, G.C. Ooi, W.K. Yee, T. Wang, M. Chan-Yeung, W.K. Lam, W.H. Seto, L.Y. Yam, and T.M. Cheung, A cluster of cases of severe acute respiratory syndrome in Hong Kong, New Engl. J. Med. 348 (2003), pp. 1977–1985. doi:https://doi.org/10.1056/NEJMoa030666.
- H. Lu, C.W. Stratton, and Y.-W. Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle, J. Med. Virol. 92 (2020), pp. 401–402. doi:https://doi.org/10.1002/jmv.25678.
- N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, and R. Lu, A novel coronavirus from patients with pneumonia in China, 2019, New Engl. J. Med. 382 (2020), pp. 727–733. doi:https://doi.org/10.1056/NEJMoa2001017.
- C. Sohrabi, Z. Alsafi, N. O’Neill, M. Khan, A. Kerwan, A. Al-Jabir, C. Iosifidis, and R. Agha, World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int. J. Surg. 1 (2020), pp. 1–6.
- Y.W. Chen, C.-P.B. Yiu, and K.-Y. Wong, Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates, F1000Res. 9 (2020), pp. 1–6. doi:https://doi.org/10.12688/f1000research.22457.2.
- G. Simmons, P. Zmora, S. Gierer, A. Heurich, and S. Pöhlmann, Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research, Antiviral Res. 100 (2013), pp. 605–614. doi:https://doi.org/10.1016/j.antiviral.2013.09.028.
- S. Ahmed, R. Mahtarin, S.S. Ahmed, S. Akter, M.S. Islam, A.A. Mamun, R. Islam, M.N. Hossain, M.A. Ali, and M.U. Sultana, Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2, J. Biomol. Struct. Dyn. 39 (2020), pp. 1–16.
- A.O. Fadaka, R.T. Aruleba, N.R.S. Sibuyi, A. Klein, A.M. Madiehe, and M. Meyer, Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: A computational-aided approach, J. Biomol. Struct. Dyn. 39 (2020), pp. 1–13.
- K. Anand, J. Ziebuhr, P. Wadhwani, J.R. Mesters, and R. Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs, Science 300 (2003), pp. 1763–1767. doi:https://doi.org/10.1126/science.1085658.
- A.K. Ghosh, M. Brindisi, D. Shahabi, M.E. Chapman, and A.D. Mesecar, Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics, ChemMedChem 15 (2020), pp. 1–8.
- A. Zhavoronkov, B. Zagribelnyy, A. Zhebrak, V. Aladinskiy, V. Terentiev, Q. Vanhaelen, D.S. Bezrukov, D. Polykovskiy, R. Shayakhmetov, and A. Filimonov, Potential non-covalent SARS-CoV-2 3C-like protease inhibitors designed using generative deep learning approaches and reviewed by human medicinal chemist in virtual reality, Anal. Chem. 1 (2020), pp. 1–7.
- L.-R. Chen, Y.-C. Wang, Y.W. Lin, S.-Y. Chou, S.-F. Chen, L.T. Liu, Y.-T. Wu, C.-J. Kuo, T.-S.-S. Chen, and S.-H. Juang, Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors, Bioorg. Med. Chem. Lett. 15 (2005), pp. 3058–3062. doi:https://doi.org/10.1016/j.bmcl.2005.04.027.
- W. Liu, H.-M. Zhu, G.-J. Niu, E.-Z. Shi, J. Chen, B. Sun, W.-Q. Chen, H.-G. Zhou, and C. Yang, Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors, Bioorg. Med. Chem. 22 (2014), pp. 292–302. doi:https://doi.org/10.1016/j.bmc.2013.11.028.
- C.-N. Chen, C.P. Lin, -K.-K. Huang, W.-C. Chen, H.-P. Hsieh, P.-H. Liang, and J.T.-A. Hsu, Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3ʹ-digallate (TF3), Evid. Based Compl. Altern. Med 2 (2005), pp. 1–10.
- L. Chen, C. Gui, X. Luo, Q. Yang, S. Günther, E. Scandella, C. Drosten, D. Bai, X. He, and B. Ludewig, Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro, J. Virol. 79 (2005), pp. 7095–7103. doi:https://doi.org/10.1128/JVI.79.11.7095-7103.2005.
- C. Niu, J. Yin, J. Zhang, J.C. Vederas, and M.N. James, Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro, Bioorg. Med. Chem. 16 (2008), pp. 293–302. doi:https://doi.org/10.1016/j.bmc.2007.09.034.
- I.-L. Lu, N. Mahindroo, P.-H. Liang, Y.-H. Peng, C.-J. Kuo, K.-C. Tsai, H.-P. Hsieh, Y.-S. Chao, and S.-Y. Wu, Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease, J. Med. Chem. 49 (2006), pp. 5154–5161. doi:https://doi.org/10.1021/jm060207o.
- K.-C. Tsai, S.-Y. Chen, P.-H. Liang, I.-L. Lu, N. Mahindroo, H.-P. Hsieh, Y.-S. Chao, L. Liu, D. Liu, and W. Lien, Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies, J. Med. Chem. 49 (2006), pp. 3485–3495. doi:https://doi.org/10.1021/jm050852f.
- J.-Y. Park, J.H. Kim, Y.M. Kim, H.J. Jeong, D.W. Kim, K.H. Park, H.-J. Kwon, S.-J. Park, W.S. Lee, and Y.B. Ryu, Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases, Bioorg. Med. Chem. 20 (2012), pp. 5928–5935. doi:https://doi.org/10.1016/j.bmc.2012.07.038.
- R.Y. Kao, W.H. Tsui, T.S. Lee, J.A. Tanner, R.M. Watt, J.-D. Huang, L. Hu, G. Chen, Z. Chen, and L. Zhang, Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics, Chem. Biol. 11 (2004), pp. 1293–1299. doi:https://doi.org/10.1016/j.chembiol.2004.07.013.
- A.J. Dooley, N. Shindo, B. Taggart, J.-G. Park, and Y.-P. Pang, From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus, Bioorg. Med. Chem. Lett. 16 (2006), pp. 830–833. doi:https://doi.org/10.1016/j.bmcl.2005.11.018.
- M. Shehroz, T. Zaheer, and T. Hussain, Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment, Heliyon 6 (2020), pp. 5278–5288. doi:https://doi.org/10.1016/j.heliyon.2020.e05278.
- M. Hassan Baig, K. Ahmad, S. Roy, J. Mohammad Ashraf, M. Adil, M. Haris Siddiqui, S. Khan, M. Amjad Kamal, I. Provazník, and I. Choi, Computer aided drug design: Success and limitations, Curr. Pharm. Des. 22 (2016), pp. 572–581. doi:https://doi.org/10.2174/1381612822666151125000550.
- P. Gramatica, Principles of QSAR modeling: Comments and suggestions from personal experience, Intern. J. Quant. Struct.-Prop. Relat. 5 (2020), pp. 1–37.
- A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, and R. Todeschini, QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 57 (2014), pp. 4977–5010. doi:https://doi.org/10.1021/jm4004285.
- U. Bacha, J. Barrila, A. Velazquez-Campoy, S.A. Leavitt, and E. Freire, Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro, Biochemistry 43 (2004), pp. 4906–4912. doi:https://doi.org/10.1021/bi0361766.
- T. Fujita and D.A. Winkler, Understanding the roles of the “two QSARs”, J. Chemical Chem. Inf. Model. 56 (2016), pp. 269–274. doi:https://doi.org/10.1021/acs.jcim.5b00229.
- V.H. Masand, S. Akasapu, A. Gandhi, V. Rastija, and M.K. Patil, Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study, Chemom. Intell. Lab. Syst. 206 (2020), pp. 104172–104181. doi:https://doi.org/10.1016/j.chemolab.2020.104172.
- V. Kumar and K. Roy, Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases, SAR QSAR Environ. Res. 31 (2020), pp. 511–526. doi:https://doi.org/10.1080/1062936X.2020.1776388.
- V. Masand, V. Rastija, M. Patil, A. Gandhi, and A. Chapolikar, Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling, SAR QSAR Environ. Res. 31 (2020), pp. 643–654. doi:https://doi.org/10.1080/1062936X.2020.1784271.
- K. Ghosh, S.A. Amin, S. Gayen, and T. Jha, Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) inhibitors, J. Molec. Struct. 1224 (2021), pp. 129026–129034. doi:https://doi.org/10.1016/j.molstruc.2020.129026.
- P. De, S. Bhayye, V. Kumar, and K. Roy, In silico modeling for quick prediction of inhibitory activity against 3CLpro enzyme in SARS CoV diseases, J. Biomol. Struct. Dynam. (2020), pp. 1–27. doi:https://doi.org/10.1080/07391102.2020.1821779.
- P. Van Tat, T.T. Hoa, A. Vo Ky, and P. Nu Ngoc Han, Novel SARS-CoV-2 Inhibitors from phenethylthiazolethiourea derivatives using hybrid QSAR models and docking simulation, Smart. Sci. (2021), pp. 1–21. doi:https://doi.org/10.1080/23080477.2021.1914967.
- R. Tibshirani, Regression shrinkage and selection via the lasso, J. Royal Stat. Soc. Seri. B (Methodol.) 58 (1996), pp. 267–288.
- J. Fan and R. Li, Variable selection via nonconcave penalized likelihood and its oracle properties, J. Am. Stat. Assoc. 96 (2001), pp. 1348–1360. doi:https://doi.org/10.1198/016214501753382273.
- H. Zou, The adaptive lasso and its oracle properties, J. Am. Stat. Assoc. 101 (2006), pp. 1418–1429. doi:https://doi.org/10.1198/016214506000000735.
- Z. Algamal and M. Lee, A new adaptive L1-norm for optimal descriptor selection of high-dimensional QSAR classification model for anti-hepatitis C virus activity of thiourea derivatives, SAR QSAR Environ. Res. 28 (2017), pp. 75–90. doi:https://doi.org/10.1080/1062936X.2017.1278618.
- Z.Y. Algamal and M.H. Lee, A novel molecular descriptor selection method in QSAR classification model based on weighted penalized logistic regression, J. Chemom. 31 (2017), pp. 1–11. doi:https://doi.org/10.1002/cem.2915.
- Z.Y. Algamal, M.H. Lee, A.M. Al‐Fakih, and M. Aziz, High‐dimensional QSAR prediction of anticancer potency of imidazo [4, 5‐b] pyridine derivatives using adjusted adaptive LASSO, J. Chemom. 29 (2015), pp. 547–556. doi:https://doi.org/10.1002/cem.2741.
- Z.Y. Algamal, M.H. Lee, A.M. Al‐Fakih, and M. Aziz, High‐dimensional QSAR classification model for anti‐hepatitis C virus activity of thiourea derivatives based on the sparse logistic regression model with a bridge penalty, J. Chemom. 31 (2017), pp. 2889–2897. doi:https://doi.org/10.1002/cem.2889.
- A. Alharthi, M. Lee, Z. Algamal, and A. Al-Fakih, Quantitative structure-activity relationship model for classifying the diverse series of antifungal agents using ratio weighted penalized logistic regression, SAR QSAR Environ. Res. 31 (2020), pp. 571–583. doi:https://doi.org/10.1080/1062936X.2020.1782467.
- M. Ebrahimi, T. Khayamian, and S. Gharaghani, Interactions between activin-like kinase 5 (ALK5) receptor and its inhibitors and the construction of a docking descriptor-based QSAR model, J. Braz. Chem. Soc. 23 (2012), pp. 2043–2092. doi:https://doi.org/10.1590/S0103-50532012005000082.
- M. Eklund, U. Norinder, S. Boyer, and L. Carlsson, Benchmarking variable selection in QSAR, Molec. Inf. 31 (2012), pp. 173–179. doi:https://doi.org/10.1002/minf.201100142.
- G. Ghasemi, S. Arshadi, A.N. Rashtehroodi, M. Nirouei, S. Shariati, and Z. Rastgoo, QSAR investigation on quinolizidinyl derivatives in alzheimer’s disease, J. Comput. Med. 300 (2013), pp. 1–10. doi:https://doi.org/10.1155/2013/312728.
- X.-L. Peng, H. Yin, R. Li, and K.-T. Fang, The application of Kriging and empirical Kriging based on the variables selected by SCAD, Anal. Chim. Acta 578 (2006), pp. 178–185. doi:https://doi.org/10.1016/j.aca.2006.06.073.
- X.-W. Zhu, Y.-J. Xin, and H.-L. Ge, Recursive random forests enable better predictive performance and model interpretation than variable selection by LASSO, J. Chem. Inf. Model. 55 (2015), pp. 736–746. doi:https://doi.org/10.1021/ci500715e.
- S. Wacker and S.Y. Noskov, Performance of machine learning algorithms for qualitative and quantitative prediction drug blockade of hERG1 channel, Comput. Toxicol. 6 (2018), pp. 55–63. doi:https://doi.org/10.1016/j.comtox.2017.05.001.
- Z. Mozafari, M.A. Chamjangali, and M. Arashi, Combination of least absolute shrinkage and selection operator with Bayesian regularization artificial neural network (LASSO-BR-ANN) for QSAR studies using functional group and molecular docking mixed descriptors, Chemom. Intel. Lab. Syst 200 (2020), pp. 103998–104011. doi:https://doi.org/10.1016/j.chemolab.2020.103998.
- Z. Mozafari, M. Arab Chamjangali, M. Arashi, and N. Goudarzi, Performance of smoothly clipped absolute deviation as a variable selection method in the artificial neural network‐based QSAR studies, J. Chemom. 35 (2021), pp. 3338–3349. doi:https://doi.org/10.1002/cem.3338.
- M. Kemp, Recent advances in the discovery of deubiquitinating enzyme inhibitors, Prog. Med. Chem 55 (2016), pp. 149–192.
- H. Herath, S. Preston, A. Jabbar, J. Garcia-Bustos, A.C. Taki, R.S. Addison, S. Hayes, K.D. Beattie, S.L. McGee, and S.D. Martin, Identification of fromiamycalin and halaminol a from australian marine sponge extracts with anthelmintic activity against Haemonchus contortus, Mar. Drugs 17 (2019), pp. 598–605. doi:https://doi.org/10.3390/md17110598.
- K. Wolinski, J. Hinton, D. Wishart, B. Sykes, F. Richards, A. Pastone, V. Saudek, P. Ellis, G. Maciel, and J. McIver, HyperChem Computational Chemistry Software Package, Version 8.0, Hypercube, Inc., Gainsville, FL, 2007.
- A. Mauri, V. Consonni, M. Pavan, and R. Todeschini, Dragon software: An easy approach to molecular descriptor calculations, Match 56 (2006), pp. 237–248.
- M. Kuhn, The Caret Package, R Foundation for Statistical Computing, R-Core team, Vienna, Austria, 2012. https://cran.r-project.org/package=caret
- N. Kraemer, J. Schaefer, and M.N. Kraemer, Package ‘Parcor’, R Foundation for Statistical Computing, R-Core team, Austria, 2014. https://cran.r-project.org/package=parcor
- W. Forli, S. Halliday, R. Belew, and A.J. Olson, AutoDock version 4.2, J. Med. Chem 55 (2012), pp. 623–638.
- S.K. Burley, H.M. Berman, C. Bhikadiya, C. Bi, L. Chen, L. Di Costanzo, C. Christie, K. Dalenberg, J.M. Duarte, and S. Dutta, RCSB protein data bank: Biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy, Nucleic Acid Res. 47 (2019), pp. D464–D474. doi:https://doi.org/10.1093/nar/gky1004.
- J. Hair Jr, R.E. Anderson, R.L. Tatham, and W. Black, Multiple discriminant analysis, Multiv. Data Anal. 3 (1995), pp. 178–256.
- L. Terfloth and J. Gasteiger, Neural networks and genetic algorithms in drug design, Drug Discov. Today 6 (2001), pp. 102–108. doi:https://doi.org/10.1016/S1359-6446(01)00173-8.
- J. Zupan and J. Gasteiger, Neural Networks for Chemists: An Introduction, John Wiley & Sons, Inc, United States, 1993.
- C. Rücker, G. Rückern, and M. Meringer, y-Randomization and its variants in QSPR/QSAR, J. Chem. Inf. Model. 47 (2007), pp. 2345–2357.
- A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graphics Modell. 20 (2002), pp. 269–276. doi:https://doi.org/10.1016/S1093-3263(01)00123-1.
- F. Sahigara, K. Mansouri, D. Ballabio, A. Mauri, V. Consonni, and R. Todeschini, Comparison of different approaches to define the applicability domain of QSAR models, Molecules 17 (2012), pp. 4791–4810. doi:https://doi.org/10.3390/molecules17054791.
- A. Daina, O. Michielin, and V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017), pp. 1–13. doi:https://doi.org/10.1038/srep42717.
- A.A. Toropov, A.P. Toropova, A.M. Veselinović, D. Leszczynska, and J. Leszczynski, SARS-CoV Mpro inhibitory activity of aromatic disulfide compounds: QSAR model, J. Biomol. Struct. Dyn. (2020), pp. 1–7. doi:https://doi.org/10.1080/07391102.2020.1818627.
- S. Khaerunnisa, H. Kurniawan, R. Awaluddin, S. Suhartati, and S. Soetjipto, Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study, Preprints 2020 (2020), pp. 30226–30231.
- M.A. Lill and M.L. Danielson, Computer-aided drug design platform using PyMOL, J. Comput. Aided Mol. Des. 25 (2011), pp. 13–19.
- P. Zhan, Z. Li, X. Liu, and E. De Clercq, Sulfanyltriazole/tetrazoles: A promising class of HIV-1 NNRTIs, Mini Rev. Med. Chem. 9 (2009), pp. 1014–1023. doi:https://doi.org/10.2174/138955709788681618.
- B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, and M. Wei, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, New Engl. J. Med. 382 (2020), pp. 1787–1799. doi:https://doi.org/10.1056/NEJMoa2001282.
- R. Yu, L. Chen, R. Lan, R. Shen, and P. Li, Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking, Int. J. Antimicr. Agents 56 (2020), pp. 106012–106019. doi:https://doi.org/10.1016/j.ijantimicag.2020.106012.
- N.A. Murugan, S. Kumar, J. Jeyakanthan, and V. Srivastava, Searching for target-specific and multi-targeting organics for Covid-19 in the drugbank database with a double scoring approach, Sci. Rep. 10 (2020), pp. 1–16. doi:https://doi.org/10.1038/s41598-020-75762-7.
- A. Hasan, B.A. Paray, A. Hussain, F.A. Qadir, F. Attar, F.M. Aziz, M. Sharifi, H. Derakhshankhah, B. Rasti, and M. Mehrabi, A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin, J. Biomol. Struct. Dyn. 39 (2021), pp. 3025–3033. doi:https://doi.org/10.1080/07391102.2020.1754293.
- M. Rehman, M.F. AlAjmi, and A. Hussain, Natural compounds as inhibitors of SARS-CoV-2 main protease (3CLpro): A molecular docking and simulation approach to combat COVID-19, Curr. Pharm. Design 27 (2021), pp. 1–12.
- D.A. Abdelrheem, S.A. Ahmed, H. Abd el-Mageed, H.S. Mohamed, A.A. Rahman, K.N. Elsayed, and S.A. Ahmed, The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: Insights from molecular docking analysis and molecular dynamic simulation, J. Environ. Sci. Health A 55 (2020), pp. 1373–1386. doi:https://doi.org/10.1080/10934529.2020.1826192.